Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46...